St. Jude Medical Announces First Clinical Trial Implant of Trifecta Stented Tissue Heart Valve

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced the first patient implant in its clinical trial of Trifecta™, a new investigational stented, pericardial tissue heart valve. The patient is the first of approximately 500 adult patients who will participate in the study. The first implant was performed by Hartzell V. Schaff, M.D., chair, Cardiovascular Surgery Division, Mayo Clinic, Rochester, Minn., and the trial’s principal investigator.

MORE ON THIS TOPIC